Evotec AG has entered a research collaboration with Harvard University to discover and develop novel anti-bacterial agents based on a validated target family in bacterial cell wall biosynthesis.   Harvard and Evotec will identify and optimize small molecule inhibitors of bacterial cell wall synthesis, based on enabling technologies and chemical starting points licensed from Harvard. Evotec will use its drug discovery infrastructure to address anti-bacterial targets, specifically peptidoglycan bi...